Lepu Medical
Lepu Medical
Engaged in the R&D, production and sales of cardiovascular disease plant intervention diagnosis and treatment equipment and cardiovascular drugs.
Lepu Medical, founded in June, 1999 and headquartered in Beijing, is an enterprise engaged in the R&D, production and sales of cardiovascular drugs and cardiovascular disease plant interventional diagnosis and treatment equipment . The founder is Pu Zhongjie. Listed on the SZSE on October 30, 2009, the company's major shareholders are Luoyang Ship Material Research Institute, Pu Zhongjie and WP Medical Technologies, INC. Rivals that have direct and indirect competition with Lepu Medical include Peijia, Kintor, Aprea Therapeutics, Viela, etc.
- All
- News
- Analysis
- Research
Briefing Jan 11, 2021 10:09 AM
· Healthcare
Xinqing medical, a domestic artificial heart and lung device enterprise, won the B round financing of over 100 million yuan from Aurora Borealis venture capital
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
In depth
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Dec 09, 2020 08:55 AM
Aug 09, 2020 12:23 AM
Briefing Nov 17, 2020 08:04 PM
· Healthcare
Plan to raise $4 billion! Jingdong health runs IPO
Briefing Oct 20, 2020 05:20 PM
· Healthcare
Neusoft Medical Launches Ten New Products and Online Shopping Mall
Briefing Oct 16, 2020 12:20 PM
· Healthcare
Varian Medical Strikes CIIE with Digital Solution for Oncology
Briefing Sep 29, 2020 06:21 PM
· Healthcare
GeneMind Biotech Closes Series B of CNY 140 Mn
Healthcare
WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry
The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.
Jan 07, 2021 02:10 PM
Real Estate, Healthcare, Automotive
WIM2020: Uniting the World through Technology and Innovation
On December 9-12, EqualOcean held the World Innovators Meet (WIM) 2020. This year, the event's main topic was 'Technology and Innovation Connect the World.' WIM2020 gathered innovators from Asia, Africa, Europe and North America to share their knowledge and key achievements, promoting the concept of 'Tech for Equal.'
Dec 17, 2020 07:53 PM
Briefing Sep 28, 2020 10:06 AM
· Healthcare
China's NMPA Reduces Paperwork for Inland Producers to Make Exotic Medical Devices
Briefing Sep 15, 2020 11:54 AM
· Healthcare
Edge Medical Robotics Closes Pre Series B at Over CNY 100 Mn
Briefing Sep 10, 2020 12:42 PM
· Healthcare
WeMed Secures CNY 100 Mn in Series C+ from GL Ventures
Briefing Sep 07, 2020 01:40 PM
· Healthcare
Singleron Biologics Receives USD 30 Mn in Series A for High-Throughput Sequencing
Briefing Sep 07, 2020 12:35 PM
· Healthcare
Surgical Robots Maker Jointech Closes Series B at Over CNY 100 Mn
Briefing Sep 04, 2020 11:24 AM
· Healthcare
Medical Imaging Maker Neusoft Cooperates with Shengjing Hospital
Briefing Sep 03, 2020 12:18 PM
· Healthcare
Mini-Invasive Medical Devices Maker Forerunner Medical Closes Series B
See more
Related Companies
EqualOcean Analysis
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.